Research shows that adding bezolizumab to chemotherapy after surgery does not increase triple negative breast cancer patients' chances of survival.

Published Date: 20 Mar 2024

Results from a large phase 3 clinical trial were presented at the 14th European Congress of Breast Cancer. They showed that patients with triple-negative breast cancer do not benefit from adding atezolizumab to their post-surgery chemotherapy treatment.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia

2.

Glioblastoma treatment breakthrough shows promise

3.

A computer-aided diagnostic system for improved detection of breast cancer.

4.

Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy

5.

Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot